No need yet for a CRO for Kevetrin. They're waiting until they have the pill form for the next clinical trial. It's futile to do another clinical trial with the IV formulation, when the plan is to have a pill form. It would be silly to spend big money on a CRO analysis for the Phase 2a IV-form clinical trial with its "promising" results, when the pill formulation is the one that would be submitted to the FDA.

When there is a deal for Bril, then the company can devote resources to continuing Kevetrin clinical trials, using the pill administration method.